Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
AffiliationCancer Research UK, Brighton and Sussex Medical School, University of Sussex, Brighton, UK. email@example.com
MetadataShow full item record
AbstractThis pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures. Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups. Patient group performance was not significantly related to length of treatment or measures of psychological morbidity. The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer. Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women. In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly.
CitationDoes hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. 2004, 13 (1):61-6 Psychooncology
- The effects of hormone therapy on cognition in breast cancer.
- Authors: Shilling V, Jenkins V, Fallowfield L, Howell T
- Issue date: 2003 Sep
- Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
- Authors: Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S
- Issue date: 2009 Aug
- Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
- Authors: van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S
- Issue date: 1998 Feb 4
- The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
- Authors: Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR
- Issue date: 2006 Feb
- Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
- Authors: Lejbak L, Vrbancic M, Crossley M
- Issue date: 2010 Oct